Clinical trial · no report yet · Phase 3
IMbrave 251
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
- NCT04770896 ↗
- Active, not recruiting
- Hoffmann-La Roche
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 18 | |
| Podcasts | 10 | |
| YouTube | 9 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Open-Label, Randomized Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Unresectable Hepatocellular Carcinoma
- Interventions
- Atezolizumab; Lenvatinib; Sorafenib
- Arms
- Atezolizumab + Lenvatinib or Sorafenib · Experimental
- Lenvatinib or Sorafenib · Active comparator
- Enrollment
- 557
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- Hoffmann-La Roche
- Start
- Apr 26, 2021
- Primary completion
- Oct 14, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04770896 · updated Aug 25, 2026